Eleven Biotherapeutics Inc. (EBIO) Sees Large Volume Increase
Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares saw unusually-strong trading volume on Tuesday . Approximately 4,786,151 shares traded hands during mid-day trading, an increase of 8% from the previous session’s volume of 4,424,656 shares.The stock last traded at $5.22 and had previously closed at $5.35.
The stock’s market cap is $76.96 million. The company’s 50-day moving average price is $3.27 and its 200 day moving average price is $1.48.
Eleven Biotherapeutics (NASDAQ:EBIO) last posted its earnings results on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter. On average, equities research analysts predict that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.
In other news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The stock was sold at an average price of $2.74, for a total value of $2,855,080.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.